All Canadians should have access to the medicines they need, and most already have coverage through existing public and private drug plans. Why is Ottawa replacing coverage that works instead of focusing on filling the gaps?
97% of Canadians are already eligible for drug coverage.
Moving to a one-size-fits-all system could limit access for Canadians who rely on cutting-edge treatments and the broader range of medicines and therapies offered through private plans. While the Pharmacare Act presents an important opportunity to improve access and reduce gaps, its design will determine whether it strengthens coverage, or puts patients at risk of losing the options they depend on.
The Government of Canada must work closely with provinces and territories to ensure Canadians have access to coverage that reflects their specific needs. IMC encourages provincial governments to engage actively in negotiations so that pharmacare investments address real, unmet needs rather than duplicating existing services or reducing the coverage Canadians currently rely on.
Read the latest news and updates on Pharmacare.
Innovative Medicines Canada (IMC) congratulates the C.D. Howe Institute on the publication of its timely and insightful report, Access and Affordability: Building Fiscally Responsible Pharmacare Systems. The report offers a well-reasoned, evidence-based contribution to one of Canada’s most important and complex health policy challenges.
Ensuring Pharmacare delivers fair access for all and innovation As originally published in The Hill Times Policy Briefing on May […]
Innovative Pharmaceutical Industry Contributed $18.4 Billion to the Canadian Economy in 2022 Ottawa, May 12, 2024 – New data released […]
Stay informed with timely, relevant content on key issues shaping our industry.
